Results 191 to 200 of about 77,919 (340)

Ferulic acid inhibits lipogenesis and ameliorates MASLD via targeting PGC-1β. [PDF]

Front Nutr
Cui K, Ren L, Zhang L, An Y, Ji P, Yang Y, Li F, Li Z.   +7 more
europepmc   +1 more source

Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease

Digestive Diseases and Sciences, 2016
Samir Softic, Samir Softic, David E. Cohen, C. Kahn   +3 more
semanticscholar   +1 more source

Population‐based cohort validation and replication reveals limited generalizability of cluster‐based MASLD subtypes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims MASLD, defined as a steatotic liver disease in the presence of one or more cardiometabolic risk factors and the absence of harmful alcohol intake, exhibits substantial heterogeneity complicating risk stratification. A prior clustering model proposed liver‐specific and cardiometabolic subtypes, yet its generalizability and prognostic ...
Junjie Wu, Weiwei Xu, Guyu Zeng, Junfeng Wang   +3 more
wiley   +1 more source

Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation. [PDF]

Oncogene
Chen J, Wang ME, Bawcom AR, Lu Y, Asara JM, Li L, Chen M.   +6 more
europepmc   +1 more source

LAT1/SLC7A5‐mediated amino acid uptake is regulated by redox signals triggered by formyl‐peptide receptor 2

The FEBS Journal, EarlyView.
FPR2 activation mediates NOX‐dependent LAT1 expression and, in turn, promotes mTORC1 signaling. Upon stimulation with WKYMVm, the FPR2‐NOX2‐ROS axis upregulates LAT1 via increased c‐Myc phosphorylation and decreased miR‐126. Additionally, it promotes CD98 translocation to the plasma membrane.
Myrhiam Cassese, Chiara Brignola, Stefano Marrone, Gabriella Esposito, Rosario Ammendola, Fabio Cattaneo   +5 more
wiley   +1 more source

Lipid Metabolism-Signaling Crosstalk in Metabolic Disease and Aging: Mechanisms and Therapeutic Targets. [PDF]

Nutrients
Sethi P, Mishra AK, Ghosh S, Singh KK, Sharma S, Stojchevski R, Avtanski D, Sinha JK.   +7 more
europepmc   +1 more source

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

Nature, 2011
Christian M. Metallo, P. Gameiro, Eric L. Bell, Katherine R. Mattaini, Juanjuan Yang, Karsten Hiller, C. Jewell, Zachary R. Johnson, D. Irvine, L. Guarente, J. Kelleher, M. V. Heiden, O. Iliopoulos, G. Stephanopoulos   +13 more
semanticscholar   +1 more source

Guidance for Liver Rehabilitation in Chronic Liver Disease

Hepatology Research, EarlyView.
ABSTRACT In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction‐associated steatotic liver disease ...
Shuji Terai, Hiroteru Kamimura, Yoichi Hiasa, Norio Akuta, Toru Ishikawa, Yuichiro Eguchi, Hironao Okubo, Takumi Kawaguchi, Miwa Kawanaka, Tatsuo Kanda, Masaaki Korenaga, Ryotaro Sakamori, Masahito Shimizu, Yoshio Sumida, Ryosuke Tateishi, Atsushi Tanaka, Naoki Tanaka, Yasuo Tanaka, Yuki Tahata, Masato Nakai, Tadashi Namisaki, Takashi Nishimura, Atsushi Hiraoka, Takeshi Matsui, Nami Mori, Akio Moriya, Tetsuo Takehara   +26 more
wiley   +1 more source

Cinnamamides, Novel Liver X Receptor Antagonists that Inhibit Ligand-Induced Lipogenesis and Fatty Liver [PDF]

, 2015
Woo-Cheol Sim, Dong Gwang Kim, Kyeong Jin Lee, You‐Jin Choi, Yeon Jae Choi, Kye Jung Shin, Dae Won Jun, So-Jung Park, Hyunju Park, Ji-Won Kim, Won Keun Oh, Byung‐Hoon Lee   +11 more
openalex   +1 more source

Modern Diets, Metabolic Inequity, and Race–Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is quickly emerging as a global public health concern, primarily fueled by the rising consumption of processed and ultraprocessed foods. This global health issue, showing a 50% increase in prevalence over two decades to 38% of the global population, is now the second most common ...
Arunkumar Krishnan, Kunal C. Kadakia, Sean Richard Rudnick, Andrew S. deLemos, James Dewitt Miller, Ted Xiao, Mark W. Russo, Dionisios Vrochides, Andrew Schreiner, Ajay Dharod   +9 more
wiley   +1 more source